12/05/13, Research and Development Phase II Data of Bayer’s Novel Cancer Drug Candidate Copanlisib to be Presented First Oral Presentation on Preliminary Phase II Data of Copanlisib (BAY 80-6946) in Patients with Indolent or Aggressive Non-Hodgkin’s Lymphoma more
11/22/13, Research and Development Nexavar® Receives Approval for the Treatment of Differentiated Thyroid Cancer in the U.S. First and only FDA-approved treatment option for patients with this type of thyroid cancer / FDA approval based on data from Phase III DECISION trial, in which sorafenib significantly extended progression-free survival compared to placebo more
|Research expenses 2012||EUR 1,556 million|
|In percent of division sales 2012
|Employees in Research & Development||7,500
(as of Dec 31, 2012)
|Main research sites||Berlin and Wuppertal, Germany and Berkeley, USA|
We hold a leading position in many therapeutic fields: for instance in the treatment of hemophilia and multiple sclerosis, in contrast media and oral contraception. We are also striving for such a leading position in oncology.
Until sufficient results are available from many different trials it is just that, potential. Effectiveness of a treatment should never be at the expense of safety; the benefit of a treatment should always outweigh the harm and is fundamental to the conduct of all clinical trials.